Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Authors

  • Athanasios Tsianakas
  • Claudia Zeidler
  • Claudia Riepe
  • Matthias Borowski
  • Caroline Forner
  • Joachim Gerss
  • Martin Metz
  • Petra Staubach
  • Ulrike Raap
  • Martin Kaatz
  • Marc Urban
  • Thomas A. Luger
  • Sonja Ständer

DOI:

https://doi.org/10.2340/00015555-3120

Keywords:

pruritus, itch, chronic nodular prurigo, substance P, neurokinin receptor 1, NK1 antagonist

Abstract

The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossed-over to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. (DRKS00005594; EudraCT Number: 2013-001601-85).

Downloads

Download data is not yet available.

Downloads

Published

2019-02-07

How to Cite

Tsianakas, A., Zeidler, C., Riepe, C., Borowski, M., Forner, C., Gerss, J., Metz, M., Staubach, P., Raap, U., Kaatz, M., Urban, M., Luger, T. A., & Ständer, S. (2019). Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). Acta Dermato-Venereologica, 99(4), 379–385. https://doi.org/10.2340/00015555-3120

Issue

Section

Articles